June 1, 2020 / 6:16 AM / a month ago

AstraZeneca-Merck Lynparza gets EMA's positive recommendation

June 1 (Reuters) - Drugmakers AstraZeneca Plc and Merck & Co Inc said on Monday their blockbluster cancer drug, Lynparza, has received positive recommendation from the European Medicines Agency (EMA) as a maintenance treatment for a form of pancreatic cancer.

The recommendation from the EMA’s Committee for Medicinal Products for Human Use was based on positive results from a late-stage trial, where Lynparza nearly doubled the time patients with gBRCAm metastatic pancreatic cancer lived without disease progression or death. (Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Vinay Dwivedi)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below